Ozempic vs Mounjaro: what actually separates them

What this guide covers

Ozempic and Mounjaro are not the same molecule and not the same class of GLP-1. Here is what genuinely differs (the drug, the mechanism, the head-to-head data, dosing, and cost) and what to make of it. This is patient education, not a substitute for the prescriber who knows your case. Generic names sit next to brand names throughout: semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound).

Key points

• The short answer: different drugs, not different labels. This is the first thing to get straight, because it is the opposite of the Ozempic-versus-Wegovy question. Ozempic and Wegovy are the same molecule under two brands. Ozempic and Mounjaro are genuinely different drugs. Ozempic is semaglutide, made by Novo Nordisk; Mounjaro is tirzepatide, made by Eli Lilly. They also share a job description: both are once-weekly injections FDA-approved for type 2 diabetes, and both are the diabetes-branded sibling of a weight-management drug (Wegovy for semaglutide, Zepbound for tirzepatide). So the real comparison here is semaglutide versus tirzepatide wearing their diabetes labels, and our semaglutide vs tirzepatide guide covers the molecule-level story in full.
• One receptor versus two. The mechanism is where they part ways. Semaglutide is a single agonist: it mimics GLP-1, a gut hormone that slows how fast the stomach empties, dampens appetite, and improves the glucose-dependent insulin response. Tirzepatide does that same GLP-1 job and also activates a second incretin receptor, GIP. That is why it is described as a dual agonist. The working idea in the trial literature is that hitting both incretin pathways is why tirzepatide tends to edge ahead on weight and blood sugar, though exactly how much GIP contributes is still an open research question rather than settled fact. The practical takeaway is simple: these are two different tools, not two doses of the same one.
• Blood sugar, head-to-head. Because both are diabetes drugs, the cleanest data is the SURPASS-2 trial (Frias 2021), which put them side by side in adults with type 2 diabetes. All three tirzepatide doses lowered HbA1c more than semaglutide 1 mg, and the gap widened at the higher tirzepatide doses. Both drugs lower blood sugar strongly, and both carry a low risk of hypoglycemia on their own. That risk climbs when either is combined with insulin or a sulfonylurea, which is a situation where the dose of the companion drug often has to come down. That is a prescriber's adjustment, not a self-directed one.
• Weight: the honest comparison. Weight change is where most people are really looking, so it deserves care. SURPASS-2 also measured weight and tirzepatide came out ahead of semaglutide 1 mg at every dose. The important caveat is that SURPASS-2 used the diabetes dose of semaglutide (1 mg), not the higher 2.4 mg obesity dose, so it was not a perfectly matched fight. When the two molecules are compared at their obesity doses (Wegovy versus Zepbound), tirzepatide has still tended to lead, and our Wegovy vs Zepbound comparison walks through that. But remember: Ozempic and Mounjaro are the diabetes brands, and weight loss with them is real but is not the labeled indication. Chasing weight loss specifically is a conversation about Wegovy or Zepbound.
• Side effects: same family, similar list. Because both work through the GLP-1 pathway, the side-effect profiles look alike: nausea, diarrhea, constipation, and vomiting lead both labels, are usually mild to moderate, and cluster in the first weeks and right after each dose increase. In the trials, gastrointestinal effects were common with both and led a single-digit percentage of people to stop. There is no strong evidence that one is reliably gentler than the other for everyone, individual tolerance varies more than the difference between the two drugs. Both also carry the class boxed warning about thyroid C-cell tumors from rodent studies, plus cautions about pancreatitis and gallbladder problems. If you are managing nausea or constipation, the approach is the same either way, which is why our symptom guides apply to both.

Frequently asked questions